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Chemotherapy-Associated Toxicity in a Large Cohort of
Elderly Patients with Non-small Cell Lung Cancer
Dale Hardy, PhD,* Janice N. Cormier, MD, MPH,† Yan Xing, MD, PhD,† Chih-Chin Liu, MS,*
Rui Xia, MS,* and Xianglin L. Du, MD, PhD*§
Background: The objective of this study was to examine the risks
for short-term (3 months) and long-term (3 months) chemother-
apy-associated toxicities in a large population-based cohort of pa-
tients with non-small cell lung cancer from 1991 to 2002.
Methods: The population consisted of 41,361 men and 30,804
women 65 years identified from the Surveillance, Epidemiology,
and End Results—Medicare-linked database. The incidence of 50
toxicity-associated end points was calculated for 14 chemotherapy
agents. Short- and long-term toxicities with a 2-fold increase in
incidence compared with the no-chemotherapy group were defined as
chemotherapy-associated toxicities. Hazard ratios and 95% confidence
intervals for the risk of toxicity were calculated for the four most
common chemotherapy agents for non-small cell lung cancer: cisplatin/
carboplatin, paclitaxel, vinorelbine/vinblastine, and gemcitabine.
Results: The most common short-term toxicities (9.2–60%) in-
cluded acute anemia, nausea, and neutropenia. The most common
long-term toxicities (15–37%) included acute anemia, respiratory
failure, pulmonary fibrosis, dehydration, neutropenia, nausea, and
fever. Multivariate analysis for selected chemotherapies demon-
strated that after adjusting for other risk factors and confounders,
some short-term toxicities became nonsignificant; however, almost
all long-term toxicities remained significant. Long-term toxicity
increased over time and was more likely in women, minority popula-
tions, those with fewer baseline comorbidities, and across disease
stages.
Conclusions: The administration of various chemotherapy agents
for non-small cell lung was associated with a number of short- and
long-term toxicities. The projected survival benefits of chemother-
apy must be weighed against the risk of long-term toxicities.
Key Words: Non-small cell lung cancer, Chemotherapy, Toxicity,
Years of diagnosis, Tumor stage, Comorbidities.
(J Thorac Oncol. 2010;5: 90–98)
Chemotherapy has been shown to improve survival andpalliate disease-related symptoms in patients with stage
IV non-small cell lung cancer (NSCLC).1 The guidelines for
the administration of specific chemotherapeutic agents en-
dorsed by the American College of Chest Physicians derived
from evidence from randomized trials and were based on
evidence that demonstrated a substantial benefit for both
survival and palliation in patients with stage IIIB and stage IV
disease with good performance status.2 To extrapolate these
treatment recommendations to additional subsets of patients
with poorer performance status or significant comorbidities, it
is critical for clinicians to have accurate estimates of the risks
that include short- and long-term toxicities of various che-
motherapy regimens and to engage patients in discussion of
preferences.
It has been suggested that the risk-benefit ratio of
treatment rendered in the setting of randomized clinical trials
may not be applicable to patients treated in the community.
There are a number of plausible explanations: (1) randomized
trials are designed to examine the efficacy of various regi-
mens in eligible patients, which often include only those with
the best performance status, and (2) randomized trials are
often performed at trial sites, which are often supported by
extensive clinical infrastructure. In such settings, acute tox-
icities associated with treatment are often identified and
managed expeditiously and long-term toxicities are not often
reported because of short-term trial follow-up, which pre-
cludes their identification. As a result, the efficacy or benefit
of treatment is often maximized while the risks of treatment
are minimized. For these reasons, it is critical to obtain
estimates of the spectrum of chemotherapy-associated toxic-
ities administered in the community using population-based
data that include older patients, ethnic minorities, and those
with comorbidities.
The first objective of this study was to determine the
incidence of short-term toxicity (3 months) and long-term
toxicity (3 months) associated with various chemother-
apy agents administered for NSCLC. An additional aim
was to determine the risks for toxicities with a 2-fold
incidence for the most common agents administered: cis-
platin and carboplatin combined (CARCIS), paclitaxel (PAC),
vinorelbine and vinblastine combined (VINVinb), and gem-
citabine (GEM) compared with the group who received
no-chemotherapy.
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METHODS
Data Sources
The Surveillance, Epidemiology, and End Results (SEER)
Program—Medicare-linked database was used to provide
information about incident cancer cases and cancer-directed
therapy, as well as Medicare eligibility, enrollment, and
claims for those 65 years.3 Patients who did not have full
coverage of both Medicare Parts A and B or who were
members of a Health Maintenance Organization after diag-
nosis through the date of last follow-up or death were ex-
cluded from the study. The University of Texas School of
Public Health at Houston Committee for Protection of Human
Subjects approved the study protocol.
Study Variables
The outcome variable was time to development (in
days) of chemotherapy toxicity-related conditions calculated
from the date of diagnosis of NSCLC to the date of toxicity,
censoring, or the last date of follow-up. The exposure vari-
able, chemotherapy, was designated as whether or not pa-
tients received one or more chemotherapy claim within 12
months of diagnosis. Patients who developed toxicities after
chemotherapy was administered were included in the analy-
sis. Patients with existing toxicity conditions before cancer
diagnosis were excluded from the study.
The following patient and tumor characteristics were
considered for covariate adjustment in multivariate analyses:
race/ethnicity was designated as whites (non-Hispanic white),
blacks (African Americans and non-Hispanic blacks from
other countries), Asians, Hispanics, other and unknown eth-
nicity; years of diagnosis (1991–2002); age (65–69, 70–74,
75–79, or 80 years); marital status (married, unmarried, or
unknown); sex (male or female); socioeconomic status (quar-
tiles of poverty), disease stage (American Joint Committee on
Cancer stages I–IV, unstaged); tumor grade (well differenti-
ated, moderately differentiated, poorly differentiated, and
unknown); positive number of nodes (1, 2–3, 4–5, 6–9, and
10–51); SEER areas (16 US regions); and surgery and radi-
ation therapy within 12 months of diagnosis. A weighted
comorbidity score (explained elsewhere)4 coded as 0, 1, 2, 3,
or 4 was calculated from comorbidities ascertained from
Medicare claims by identifying 18 diagnoses or related pro-
cedures recorded between 1 year before and 1 month after the
diagnosis of NSCLC. Comorbidities before the year of cancer
diagnosis could not be ascertained.
Chemotherapy
Chemotherapy is recommended as part of standard ther-
apy for patients with NSCLC according to the National Com-
prehensive Cancer Network guidelines.5 For stages I–IIIA dis-
ease, as an adjunct treatment to surgical resection, chemotherapy
with or without chemoradiation is given. For stages IIIB and IV
disease, chemotherapy and radiation therapy are recommended.
In brief, patients who were treated with chemotherapy
were identified using the ICD-9 procedure code 9925 for
injection or infusion of cancer chemotherapeutic substance,
current procedural terminology (CPT) codes (96400-96549,
J8510, J8520, J8521, J8530-J8999, J9000-J9999, and Q0083-
Q0085) for chemotherapy administration, revenue center
codes 0331 (chemotherapy injected), 0332 (chemotherapy
oral), 0335 (chemotherapy intravenous), and ICD-9-CM V
codes (V58.1, V66.2, or V67.2) for follow-up examination
or care after chemotherapy. Surgery and radiation therapy within
12 months of diagnosis were identified from SEER codes,6
ICD-9 procedure codes,7,8 and CPT codes8,9 as referenced.
Statistical Analysis
Analyses were performed using STATA, version 10.1
(STATACORP, College Station, TX) and SAS, version 9.1
(SAS Institute Inc., Cary, NC). Descriptive statistics for
patients who received and did not receive chemotherapy for
all covariates were performed using Pearson’s 2 tests of
hypothesis for independence with p value of 0.05 as the
cut-off point (Table 1). The observed incidence rates for
developing short-term (3 months) and long-term (3
months) chemotherapy toxicities were calculated as a per-
centage of 14 different chemotherapy agents for 50 toxicity-
related end points (Tables 2 and 3). The toxicities were then
categorized as 2-fold increase, 1.5- to 2-fold increase,
and 1- to 1.5-fold increase by comparing the incidence of a
specific toxicity with the incidence observed in the cohort of
patients who did not receive chemotherapy. Chemotherapy-
associated toxicity was subsequently arbitrarily defined as a
2-fold increase in percent above the level of that seen in the
no-chemotherapy group.
An ordinal logistic regression analysis using a propor-
tional odds model with composite toxicity scores was used to
compute the odds ratios (ORs) and 95% confidence intervals
(CIs) of developing long-term toxicities across toxicity levels
for age, gender, racial/ethnic groups, stage, comorbidity
scores, and year of diagnosis (Table 4). Long-term toxicities
levels were categorized as: 0, no toxicity; 1, only 1 toxicity;
and 2, having 2 to 9 toxicities. Additionally, Cox proportional
regression analyses were then performed for short- and long-
term toxicities associated with the more commonly adminis-
tered four groups of chemotherapy agents: CARCIS, PAC,
VINVinb, and GEM (Table 5). Bonferonni-Sidak correction
was used to control for the false discovery rate from multiple
comparisons testing.10 Effect modifiers were identified for
chemotherapy (the exposure variable) and the covariates
using the likelihood ratio test with a p value cut-off point of
0.05. When the proportional hazards assumption was vio-
lated, time varying covariates were constructed to address
variables that interacted with time. Both effect modifiers and
time dependent covariates were added to the multivariate
model.
RESULTS
The study population consisted of 41,361 (57.3%) men
and 30,804 (42.7%) women, 65 years, diagnosed with
NSCLC between January 1, 1991, and December 31, 2002.
The median survival time for the short- and long-term che-
motherapy toxicity composite groups that were more than or
equal to two times that of the no-chemotherapy group was 29
and 241 days, respectively. Patients who received chemother-
apy had a lower median age (72 years) compared with those
who did not received chemotherapy (75 years) (Table 1). As
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anticipated, only a small fraction of patients receiving che-
motherapy had stage I and stage II disease (8.3% and 5.3%,
respectively). More than one-third of patients who received
chemotherapy had a tumor size 4 cm, poorly-differentiated
tumors, and adenocarcinoma. The chemotherapy cohort has a
lower percentage of patients with comorbidity scores 2 at
baseline compared with the no-chemotherapy cohort.
Tables 2 and 3 display the short-term (3 months) and
long-term (3 months) incidence rates for developing vari-
ous chemotherapy-associated toxicities stratified by chemo-
therapy agent. The overall incidence categories were classi-
fied according to the results for CARCIS, and as such, there
may be variation for other agents. Most importantly, in
chemotherapy claims, the incidence of “adverse effects of
antineoplastics” was reported as only 1.9 to 4.4% for short-
term toxicities (Table 2) and 2 to 10% for long-term toxicities
(Table 3), which vastly underestimates the overall chemo-
therapy-associated toxicities when compared with the inci-
dence identified in claims when individual toxicity end points
were assessed.
The most common short-term (3 months) toxicities
included acute anemia (20–35.9%), nausea (20.1–60%), and
neutropenia (9.2–22.5%) (Table 2). Other less common short-
term toxicities were thrombocytopenia (2.6–6.2%), diarrhea
(2.6–10%), stomatitis (0.6–1.4%), hemolytic anemia (0.4–
1.6%), and leukemia (0.2–0.8%). In general, unlike long-
term toxicities, there was little variability in the incidence of
short-term toxicities for the various agents. The most com-
mon long-term toxicities included acute anemia (30.7–37.6%),
dehydration (24.9–33.6%), respiratory failure (26.3–40.8%),
pulmonary fibrosis (25–33.3%), neutropenia (17.0–33.3%),
nausea (16.0–25.6%), and fever (13.3–20%). Less common
toxicities that occurred with an incidence of2-fold increase
in the incidence compared with the no-chemotherapy group
included deep vein thrombosis, thrombocytopenia, hypoten-
sion, peripheral neuropathy, myocarditis, syndrome of inap-
propriate antidiuretic hormone secretion, stomatitis, dermati-
tis, and leukemia.
When individual toxicity end points were examined for
nonplatinum based agents, the incidence of long-term che-
motherapy-associated toxicities was much higher (Table 3).
This was most evident for the long-term toxicity associated
with docetaxel (DOC) and ifosfamide (IFO). DOC was asso-
ciated with the highest incidence of pancytopenia (anemia,
neutropenia, and thrombocytopenia) as well as pulmonary,
cardiac, hepatocellular, gastrointestinal, mental status, infec-
tious, and renal complications. Similarly, IFO was also asso-
ciated with long-term pancytopenia, nausea, and pulmonary
fibrosis and had the highest incidence of cardiomyopathy
(7.0%), renal failure (17.1%), drug psychoses (6.2%), and
encephalopathy (3.1%). There were some rare long-term
toxicity end points, which were noted in this study that have
not been identified in clinical trials. These are bolded and
highlighted in gray (Table 3). These toxicities include pul-
monary embolism (1.6–3%) associated with fluorouracil
(FLU), mitomycin (MIT), leucovorin (LEU), and doxorubi-
cin (DOX) which is 4- to 5-fold greater than in the no-
TABLE 1. Characteristics of Patients with Non-small Cell Lung
Cancer by Chemotherapy Status within 12 mo of Diagnosis
Characteristics
Number and
Column % of Cases
No-
Chemotherapy
(n  50,632)
Chemotherapy
(n  21,533)
n % n %
Median age (range) 75 (65–89) 72 (65–89)
Age (yr)
65–69 11,273 22.3 17,259 33.7
70–74 13,615 26.9 7267 33.8
75–79 13,248 26.2 4740 22.0
80–84 8754 17.3 1826 8.5
85–89 3742 7.4 441 2.1
Race/ethnicity
Caucasian 41,788 82.5 18,184 84.5
African American 4782 9.4 1761 8.2
Asian 1490 2.9 636 3.0
Hispanic 570 1.1 232 1.1
Other race 1625 3.2 626 2.9
Unknown 377 0.7 94 0.4
Gender
Male 28,588 56.5 12,773 59.3
Female 22,044 43.5 8760 40.7
Unknown 1920 3.8 744 3.5
Tumor stage
I 11,190 22.1 1786 8.3
II 4104 8.1 1143 5.3
IIIA 4492 8.9 3010 14.0
IIIB 9352 18.5 5129 23.8
IV 16,497 32.6 8863 41.2
Unstaged 4997 9.9 1602 7.4
Tumor size (cm)
1 538 1.1 154 0.7
1–1.9 3085 6.1 711 3.3
2–2.9 6084 12.0 1977 9.2
3–3.9 6001 11.9 2373 11.0
4 15,863 31.3 7569 35.2
Missing 19,061 37.7 8749 40.6
Tumor grade
Well differentiated 2246 4.4 611 2.8
Moderately differentiated 8347 16.5 2823 13.1
Poorly differentiated 16,832 33.2 7614 35.4
Undifferentiated 2874 5.7 1308 6.1
Unknown/missing 20,333 40.2 9177 42.6
Histology
Carcinoma, nonspecific 10,289 20.3 4653 21.6
Large cell 3961 7.8 1795 8.3
Squamous cell 15,861 31.3 5737 26.6
Adenocarcinoma 17,676 34.9 8490 39.4
Bronchus 2101 4.2 574 2.7
Adenosquamous cell 744 1.5 284 1.3
Comorbidity scores
0 17,486 34.5 9722 45.2
1 17,660 34.9 7573 35.2
2 8074 16.0 2627 12.2
3 3480 6.9 1008 4.7
4 3932 7.8 603 2.8
Surgery
No 37,579 74.2 18,521 86.0
Yes 13,053 25.8 3012 14.0
Radiotherapy
No 27,323 54.0 6486 30.1
Yes 23,309 46.0 15,047 69.9
All p values were0.0001 and calculated using Pearson’s 2 tests of hypothesis for
independence to assess statistical significance between chemotherapy groups.
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chemotherapy group. Likewise, seizures (3.5–5%) were associ-
ated with FLU, MIT, cyclophosphamide, LEU, and DOX.
Table 4 shows the results of the ordinal logistic regres-
sion analysis (ORs and 95% CI) for the effect across toxicity
response levels for long-term toxicities adjusted for various
clinical and pathologic covariates. Patients who received
chemotherapy had an adjusted OR  4.44 (95% CI: 3.85–
5.12) for long-term toxicity, which was an augmented effect
when compared with the unadjusted crude model (OR 
3.27, 95% CI: 3.17–3.37). Women (OR  1.29, 95% CI:TA
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TABLE 4. Multivariable Analysis of Risk Factors for
Long-Term Chemotherapy-Associated Toxicity
Proportional Odds Ratio (95% Confidence
Interval)Long Term Toxicity >3 mo
Chemotherapy
No 1.00
Yes 4.44 (3.85–5.12)
Age (yr)
65–69 1.00
70–74 0.99 (0.95–1.04)
75–79 1.04 (0.99–1.10)
80–84 1.03 (0.97–1.10)
85–89 1.06 (0.97–1.15)
Gender
Men 1.00
Women 1.29 (1.24–1.34)
Race/ethnicity
Caucasian 1.00
African American 1.37 (1.29–1.45)
Asian 1.73 (1.58–1.89)
Hispanic 1.42 (1.22–1.64)
Other race 1.12 (1.03–1.23)
Unknown 0.72 (0.58–0.89)
Disease stage
IV 1.00
IIIB 1.74 (1.66–1.82)
IIIA 2.46 (2.32–2.61)
II 3.04 (2.84–3.25)
I 3.83 (3.63–4.04)
Unstaged 3.06 (2.88–3.25)
Comorbidity scores
4 1.00
3 1.27 (1.16–1.39)
2 1.24 (1.15–1.35)
1 1.27 (1.18–1.37)
0 1.37 (1.26–1.48)
Year of diagnosis
1991–1995 1.00
1996–1999 1.13 (1.09–1.18)
2000–2002 1.15 (1.10–1.20)
Odds ratios calculated using a proportional odds model (toxicity outcome level: no
toxicity  0, one toxicity  1, and 2–9 toxicities  2). Multivariate analysis adjusted
for age, race, gender, socioeconomic status, tumor stage, number of positive lymph
nodes, tumor grade, histology, comorbidity scores, surgery, radiation therapy, SEER
areas, years of diagnosis, and interaction terms for chemotherapy with gender, surgery,
age, and years of diagnosis.
SEER, Surveillance, Epidemiology, and End Results.
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1.24–1.34) were noted to be more likely to develop long-term
toxicity than men. The risk of having long-term toxicity
increased for other ethnic groups compared with Caucasians
(OR: 1.12–1.37), those with localized disease stage (stage I:
OR 3.83, 95% CI: 3.63–4.04; stage II OR 3.04, 95% CI:
2.84–3.25) compared with those with stage IV NSCLC, and
those with no comorbidities (OR 1.37, 95% CI: 1.26–1.48)
compared with those with 4 comorbidities. Similarly,
newer regimens administered from 1995 to 2002 were more
likely to be associated with a small increase in long-term
toxicity.
Table 5 shows hazard ratios (HR) and 95% CI associ-
ated with developing specific short- and long-term toxicities
after adjusting for other risk factors and confounders. The
individual toxicities included in the analysis were noted to
have an incidence of 2-fold greater than the no-chemother-
apy group for the specific agents: CARCIS, PAC, VINVinb,
and GEM. There was a similar trend for the risk of hemolytic
anemia and nausea for the various agents for the short-term
toxicities. The platinum-based agents (CARCIS) were most
strongly associated with developing neutropenia (HR 9.41,
95% CI: 7.71–11.48). Stomatitis was significant only for
CARCIS and VINVinb, and thrombocytopenia for GEM.
However, when Bonferonni-Sidak adjustment for multiple
comparisons was applied, only neutropenia and nausea for
the four chemotherapies, stomatitis for CARCIS, and throm-
bocytopenia for GEM remained significant. Most of the
long-term toxicities remained significantly associated with
each of the chemotherapy agents examined after adjusting for
other factors with the exception of dehydration for GEM and
respiratory failure for CARCIS. The HR associated with nausea
was similar for short- and long-term toxicities. Thrombocytope-
nia was noted to be a significant long-term toxicity for all four
chemotherapy agents. The risk of associated neutropenia
increased over time. For example for CARCIS, the risk for
neutropenia increased from 9.41 (95% CI: 7.71–11.48) to
14.56 (95% CI: 12.69–16.71), and for PAC, the risk in-
creased from 3.08 (95% CI: 2.86–3.31) to 8.17 (95% CI:
5.67–11.77). All long-term toxicities remained statistically
significant except for fever for CARCIS, despite Bonferonni-
Sidak adjustment for multiple comparisons.
DISCUSSION
In this study, chemotherapy administration was associ-
ated with significant short-term (3 months) and long-term
(3 months) toxicities. The majority of short-term toxicities
noted were anemia, nausea, and neutropenia and are well
described in clinical trials.11–13 Female patients with localized
disease stages (I and II) and with less comorbidities were
more likely to have long-term toxicity. In multivariate anal-
ysis, platinum-based agents were associated with the greatest
short-term toxicity and with the most significant risk for
neutropenia, whereas GEM was associated with the highest
TABLE 5. Multivariate Analyses of Common Short-Term and Long-Term Toxicities for Single
Chemotherapy Agents
Toxicity Condition
Hazard Ratio (95% Confidence Interval)
>CARCIS >PAC >VINVinb >GEM
Short-term toxicity 3 mo
Acute anemia 1.09 (0.96–1.25) 0.86 (0.69–1.06) 1.04 (0.86–1.27) 0.93 (0.64–1.36)
Diarrhea 1.00 (0.73–1.38 1.00 (0.86–1.15) 0.88 (0.72–1.08) 1.11 (0.93–1.33)
Hemolytic anemia 1.79 (1.26–2.53) 1.60 (1.07–2.39) 2.10 (1.34–3.29) 1.84 (1.14–2.95)
Leukemia 1.13 (0.70–1.82) 0.89 (0.47–1.66) 1.33 (0.67–2.66) 1.67 (0.86–3.22)
Nausea 4.80 (4.16–5.55)a 3.38 (2.65–4.31)a 2.92 (2.28–3.75)a 5.63 (3.93–8.06)a
Neutropenia 9.41 (7.71–11.48)a 3.08 (2.86–3.31)a 1.49 (1.18–1.87)a 2.42 (2.25–2.63)a
Stomatitis 1.69 (1.28–2.23)a 1.34 (0.97–1.86) 1.78 (1.24–2.59) 1.12 (0.72–1.72)
Thrombocytopenia 1.19 (0.91–1.55) 0.90 (0.78–1.05) 0.89 (0.73–1.09) 1.83 (1.56–2.14)a
Long-term toxicity 3 mo
Acute anemia 2.14 (2.05–2.23)b 1.82 (1.51–2.21)b 2.31 (2.00–2.67)b 1.60 (1.19–2.16)b
Dehydration 1.55 (1.13–2.12)b 1.43 (1.15–1.79)b 1.78 (1.51–2.09)b 1.27 (0.86–1.90)
Deep vein thrombosis 2.06 (1.58–2.67)b 2.43 (1.98–2.97)b 1.75 (1.47–2.10)b 1.73 (1.16–2.59)b
Fever 1.54 (1.08–2.19) 1.83 (1.63–2.06)b 1.82 (1.60–2.09)b 1.89 (1.67–2.15)b
Nausea 3.46 (2.91–4.11)b 3.08 (2.26–4.22)b 2.34 (2.25–3.33)b 4.25 (2.72–6.65)b
Neutropenia 14.56 (12.69–16.71)b 8.17 (5.67–11.77)b 4.04 (2.93–5.58)b 7.79 (4.64–13.09)b
Pulmonary fibrosis 1.69 (1.56–1.83)b 1.92 (1.66–2.22)b 1.80 (1.59–2.04)b 1.67 (1.47–1.89)b
Respiratory failure 1.13 (0.94–1.36) 1.40 (1.29–1.53)b 1.35 (1.22–1.50)b 1.74 (1.59–1.90)b
Thrombocytopenia 3.62 (1.87–7.04)b 3.10 (1.75–5.49b 2.49 (173–3.58)b 3.50 (2.66–5.16)b
Multivariate models adjusted for age, race, gender, socioeconomic status, tumor stage, number of positive lymph nodes, tumor grade,
histology, comorbidity scores, surgery, radiation therapy, SEER areas, year of diagnosis, and various individual model interaction terms. Bold
indicates hazard ratios 0.05.
a p  0.007 using Bonferonni-Sidak adjustment for multiple comparisons testing.
b p  0.006 using Bonferonni-Sidak adjustment for multiple comparisons testing.
CARCIS, carboplatin and cisplatin combined; PAC, paclitaxel; VINVinb, vinorelbine and vinblastine combined; GEM, gemcitabine;
SEER, Surveillance, Epidemiology, and End Results.
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risk of nausea. Pancytopenia was the most commonly noted
long-term toxicity.
Toxicities for individual agents have been documented
in a number of studies that included elderly patients with
advanced NSCLC.14–17 Moreover, the toxicity and efficacy of
various chemotherapy agents as single or in combination
regimens over the course of treatment have been com-
pared.17–21 Cisplatin in combination with vinorelbine was
associated with bone marrow toxicity, leukopenia, and neu-
tropenia.19 GEM in combination with other chemotherapy
agents has been reported to be associated with nausea, vom-
iting, anemia,19 neutropenia, fatigue,22 dyspnea, neutropenia
infections, and thrombocytopenia.23 In this study, the degree
of long-term toxicity increased incrementally with less ad-
vanced disease stages. Some oncologists believe that toxici-
ties may be an indication of the efficacy of treatment.24
Overall, the findings are in concordance with short-
term toxicities seen in this current claims-based study and
those commonly reported in clinical trials.11–13 More impor-
tantly, our study reported on the long-term chemotherapy-
associated toxicities with DOC and IFO, which are not
commonly reported in clinical trials. There were also some
rare long-term toxicities identified with FLU, MIT, LEU,
DOX, and cyclophosphamide.
The strengths of this study include the large sample
size, which provides sufficient power to examine individual
chemotherapy agents and specific toxicities. In addition, a
large no-chemotherapy cohort enabled us to stratify the inci-
dence of toxicity into three levels. Furthermore, we were able
to ascertain risks by creating a composite risk score for
long-term toxicity and for the four most common chemother-
apies. There are several limitations associated with this study.
First, the study included only Medicare patients 65 years,
so results may not be generalizable to younger age groups.
Second, the actual doses of individual agents administered
were not captured in the claims data. This study relied on
CPT codes that specified standard dose for each chemother-
apy agent, but in practice, physicians may have modified a
standard chemotherapy dose for an individual patient accord-
ing to preexisting medical conditions or tolerability. The
findings that patients with localized disease stages (I and II)
and with less comorbidities were also at greater risk is likely
related to higher dosing administered to healthier patients,
which was not accounted for in this analysis. Third, although
Medicare claims on overall chemotherapy administration
have been externally validated, the validity of claims on
toxicities has not been well studied. Furthermore, although
the incidences of the 50 toxicity-associated end points were
analyzed for 14 chemotherapy agents, multimodal combina-
tion chemotherapy regimens administered varied widely and
were not analyzed separately. The unavailability of data,
which allows classification for “grade of toxicity,” is a sig-
nificant limitation to our study. We can make the assumption
that the most significant toxicities (grades III and IV) were
more likely to be included in Medicare claims, whereas grade
I and II toxicities may less likely be included.
The ultimate goal of systemic chemotherapy is to ex-
tend survival. The decision to administer more aggressive
chemotherapy regimens may be justified for patients with
NSCLC who have the potential for prolonged survival. How-
ever, long-term chemotherapy-associated toxicities must be
examined and carefully considered. Although regimens that
contain DOC and IFO have been reported to have higher
response rates in some populations, the increased long-term
toxicity profile must be carefully studied. While some toxic-
ities such as nausea and vomiting can be managed success-
fully pharmacologically,25 other less common long-term
toxicities may prove otherwise. The projected benefit to
increase survival must be weighed against the discomfort
of nonlife threatening toxic conditions resulting from
chemotherapy.
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